Description: Vildag-M combines two oral hypoglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes. Vildagliptin, a member of the islet enhancer class and Metformin, a member of the biguanide class.
Indication:
Vildag-M is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. Treatment of type 2 diabetes should not be initiated with this fixed-dose combination.